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ABSTRACT 
In this study, the concept of targeted photodynamic 
therapy, a method to induce cell death, was tested 
for epithelial ovarian cancer. Therefore, a 
recombinant single-domain antibody (7D12) was 
conjugated site-specifically to the photosensitizer 
IRDye700Dx by sortase-mediated transpeptidation 
(sortagging) and click chemistry. Cell binding and 
phototoxicity of these conjugates was evaluated in 
vitro in three different cell lines with different 
levels of epidermal growth factor receptor (EGFR)-
expression.  
It was demonstrated that targeting of IRDye700Dx 
with 7D12 lead to specific binding of these 
conjugates to high EGFR-expressing cells, allowing 
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INTRODUCTION 
Epithelial ovarian cancer is one of the four leading 
causes of cancer-related death in women. The 
disease is characterized by a general asymptomatic 
presentation, which leads to a late diagnosis. Due to 
this reason, most women show at least extensive 
abdominal spread when the disease is detected, 
leading to a poor prognosis. Patients with advanced 
stage ovarian cancer are routinely treated with 
surgery and adjuvant chemotherapy. [1, 2] Despite 
this aggressive standard treatment, the 5-year 
survival rate of these advanced stage patients is no 
more than 30 percent. [3] Therefore, more effective 
treatment modalities are absolutely needed. [1] 
 
The concept of photodynamic therapy 
Photodynamic therapy (PDT) is a method to induce  
cell death through administration and activation of 
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a so-called photosensitizer (PS) by application of 
light of a particular wavelength to the diseased area. 
Activation of the PS results in the formation of 
reactive oxygen species (ROS), leading to cell 
death. [4] PDT promises to become of great 
importance for cancer treatment in the future and is 
potentially a more effective treatment modality for 
epithelial ovarian cancer compared to the standard 
treatment. [5] 
In this study, the concept of PDT was tested for 
epithelial ovarian cancer because patients show 
especially extensive abdominal spread and PDT 
may be applied locally in the peritoneum. It is of 
major clinical relevance that the tumors are 
accessible for the PS molecules as well as for light 
application. Both aspects are given by applying 
PDT locally in the peritoneum, making ovarian 
cancer suitable for treatment with PDT. 
 
Improving tumor selectivity with targeting 
molecules 
One challenge concerning PDT is a lack of tumor 
selectivity. The preferential uptake of the PS by 
malignant tissues is often not selective enough, 
leading to off-target toxicity as well. [6] To 
improve the tumor selectivity, special delivery 
systems and targeting molecules can be used for 
targeted delivery of the PS to the tumor.  
One possible solution, which combines improved 
tumor selectivity with a more rapid clearance of 
unbound conjugates in comparison to monoclonal 
antibody (mAb)-PS conjugates, is the usage of 
recombinant single-domain antibodies (so called 
nanobodies (NBs)) for targeted delivery. [7] NBs 
consist of a monomeric antibody domain, which 
still has full antigen binding capacity. [4] 
In ovarian cancer, there are several tumor-
associated antigens known. One of them is the 
epidermal growth factor receptor (EGFR). [2]  
 
The aim of this study was to develop PDT agents 
for future treatment of ovarian cancer by 
conjugating a NB targeting EGFR (7D12) site-
specifically to the PS IRDye700Dx. Cell binding 
and phototoxicity of these conjugates was evaluated 
in vitro.  
Based on the literature it can be hypothesized that 
targeting of the PS with a NB would lead to specific 
binding of the conjugates to EGFR-expressing cell 
lines allowing cell killing of only these cells after 





Three different cell lines with different levels of 
EGFR-expression were used in this project. The 
human epidermoid squarmous carcinoma cell line 
A431 (high EGFR expression), the human ovarian 
carcinoma cell line SKOV-3 (moderate EGFR 
expression) and the human E98 glioma cell line 
were cultured in Dulbecco’s Modification of Eagle 
Medium (DMEM) containing 4.5 g/L glucose and 
L-glutamine and supplemented with 40 µg/ml 
gentamicin and 10% Fetal calf serum (FCS) at 
37¹C and 5% CO2. 
 
Production and purification of NBs 
The NB 7D12 was produced with a pelB leader 
sequence at the N-terminus and a C-terminal 
LPETG sequence and His-VSV tag by Escherichia 
coli ER2566 cells, transformed with pHENIX-
7D12-LPETG-HIS-VSV plasmid. Standard 
protocols for extraction of periplasmic proteins 
were followed and purification of the his-tagged 
NBs was performed using NI-NTA sepharose beads 
and BIO-RAD columns, because only his-tagged 
proteins are able to bind to those beads. The protein 
concentrations were measured with Nanodrop 
proteinA280 and purity was analyzed by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) 
using 15% gels.  All gels were imaged with an 
Odyssey Infrared scanner. Purity was also analyzed 
by liquid chromatography-mass spectrometry (LC-
MS; HPLC part: Shimadzu HPLC, MS part: 
Thermo Finnigan LCQ Fleet). 
 
Synthesis of 7D12-IRDye700Dx conjugates 
The 7D12-IRDye700Dx conjugates have been 
produced by sortase-mediated transpeptidation 
(sortagging) and click chemistry. This is a two-step 
reaction in which two already correctly folded 
proteins can be covalently linked resulting in an 
unnaturally linked fusion protein. First, the NB 
7D12-LPETG-His-VSV was functionalized with 
the click chemistry tool H2N-PEG4-DBCO using 
WT sortase (Addgene, Plasmid #21931). 
Subsequently, the photosensitizer IRDye700Dx, 
available as NHS ester (hereafter named PS), was 
functionalized with another chemical reactive 
group, the H2N-PEG3-N3.  
These chemical reactive groups can then be used 
for copper free click chemistry. This refers to a 
reaction in which an azide (N3) reacts with a 
strained cyclooctyne, like dibenzocyclooctyne 
(DBCO), thereby forming a covalent bond. 
Therefore, the PS-solution was incubated with the 
NBs at a 2-fold excess of PS-PEG3-N3 to VHH-
LPET-PEG4-DBCO ratio. All solutions were 
washed using Amicon® centrifugal filter devices 
and efficiency of the click chemistry reactions were 
examined using SDS-page. 
 
Cell binding experiments with the 7D12-PS 
conjugates 
Fluorescent microscopy (EVOS) was used to 
examine whether the 7D12-PS constructs retained 
cell binding capacity. SKOV-3 and A431 cells as 
well as E98 cells, as negative controls, were 
detached with trypsin and seeded in 96-well plates 
(3000 cells/well; E98: 10 000 cells/well) overnight. 
After 1 h incubation with the 7D12-PS conjugates 
(4 µM) at 4¹C, the cells were washed three times 
with PBA to remove unbound conjugates. Binding 
efficiency was analyzed with an Odyssey Infrared 
scanner and fluorescent microscopy (EVOS® FL 
Cell Imaging System) at 700 nm.  
 
Cell viability assessment after PS treatment and 
LED illumination in vitro  
The activity of all successfully synthesized 
conjugates was tested in vitro through light 
application- and light induced cell killing 
experiments. SKOV-3 and A431 cells as well as 
E98 cells, as negative controls, were detached with 
trypsin and seeded in 96-well plates (8000-20 000 
cells/well). For each experiment, a duplicate plate 
was prepared as control without illumination. The 
cells were incubated with the 7D12-PS conjugates 
in various concentrations (100, 50, 10, 5 and 1 
ng/µl) for 2 h at 37¹C. After incubation, the media 
were changed to remove the unbound particles. 
Then, cells were exposed to LED-light (7.66 
mW/cm² for 15 min, reaching a total light dose of 
6,9 J/cm²). After illumination the cells were 
cultured further and the next day, cell killing was 
examined using MTT assays. Cells were incubated 
with 10 µl (added to cells in 100 µl media: 0.1%) of 
MTS-reagent (Promega, cat.no. G3580) in the 
incubator at 37¹C and protected from light. 1h, 2h, 
4h or 6h after adding the MTS-reagent, the ELISA 
reader at 482nm was used for measurements and 
the relative viability in percentage (%), related to 
cells without treatment, was calculated. In each 
experiment four wells were treated with the same 
concentration, making it possible to calculate an 
average and the standard deviation for each 
concentration. The results are expressed in different 
graphs using Excel and the GraphPadPrism 5.03 




Production and purification of NBs 
After purification, only one remaining band can be 
observed in lane 5 on SDS page (Figure 1), 
displaying the purity of the obtained product. The 
results of LC-MS prove that the mass of this protein 
product correspond with the mass of 7D12-LPETG-
His-VSV. Therefore, it can be concluded that 
production as well as purification have been 
successful.  
 
Synthesis of 7D12-PS conjugates 
After conjugating a click chemistry tool to the PS, 
those PS molecules were mixed with the 
functionalized NBs. Starting materials as well as 
the click reaction mixtures were analyzed by SDS-
PAGE. The clear shift of the molecular weight after 
the click reaction indicates an increase in mass of 
the NB 7D12 and thus a successful conjugation of 
the PS to the NB (Figure 2). Only traces of free PS 




Figure 1: SDS-PAGE after purification of 7D12-LPETG-His-
VSV (lane 5). The molecular weight marker, the non-purified 
product, the non-bound fraction and the pre-elution during 
nickel-bead purification are represented respectively in lane 1, 2, 
3 and 4. 
 
Figure	   2:	   SDS-­‐PAGE	   after	   click	   reaction	   between	   IRDye-­‐PEG3-­‐N3	   and	   7D12-­‐LPET-­‐PEG4-­‐DBCO	   (lane	   4).	   Lane	   1	  represents	  the	  molecular	  weight	  marker	  and	  in	  lane	  2	  7D12-­‐LPET-­‐PEG4-­‐DBCO	   is	   shown.	   Lane	   3	   shows	   the	   reaction	  mixtures	   after	   the	   first	   round	  of	   purification.	   Lane	  4	   shows	  the	  product	  after	  the	  second	  round	  of	  purification. 
Cell binding experiments with the 7D12-PS 
conjugates 
Fluorescent microscopy (EVOS) was used to 
examine whether the 7D12-PS constructs have 
retained binding capacity. The compounds were 
incubated with SKOV-3 cells, with A431 cells as 
positive control and with E98 cells as negative 
controls. Only after incubating the 7D12-PS 
conjugates with the A431 cells, a clear fluorescent 
signal could be detected with the EVOS.  
 
Cell viability assessment after PS treatment and 
LED illumination (performed in Kuopio) 
The 7D12-PS conjugates clearly lead to strong 
PDT-induced toxicity after incubation and 
illumination of the EGFR-positive A431 cells 
(Figure 3). With the two highest concentrations all 
cells are dead after treatment. After incubation with 
the EGFR-negative E98 cells this cell killing effect 
cannot be observed (Figure 3), indicating successful 






Figure 3: Results after PDT in vitro. A431 cells, E98 cells and 
SKOV-3 cells were incubated with a concentration range of t 
7D12-IRDye for 2 h and exposed to LED light for 15 min. The 
next day, the relative viability in percentage (%, shown on the y-
axis), related to cells without treatment, was determined. On the 
x-axis the sample concentration (in ng/µl) is shown. Data are 
means and error bars are depicted. 	  
In contrast to the A431 cells, with the SKOV-3 
cells the cell killing effect is not that obvious 
(Figure 3). However, there is definitely a clear 
difference in relative cell viability between the 
illuminated experiments in comparison to the non-
illuminated experiments. Without illumination there 
are more cells alive than after illuminating the 
7D12-PS conjugates, indicating that there is an 
effect as well, only to a less extent. 
Importantly, in all cell lines no dark toxicity was 
detected. That means that no cell killing occurred at 
the control plates without illumination. No cell 
killing was detected with free IRDye as well. 
 
DISCUSSION 
The concept of targeted photodynamic therapy 
(PDT) is a rapidly increasing research field, which 
promises to become of great importance for cancer 
treatment in the future. [5] Different approaches 
aimed to improve the tumor selectivity of the PSs 
by conjugating them to mAbs, but those targeting 
systems still have major drawbacks because of their 
long half-lives. [8] In this study, much smaller 
nanobodies have been used as targeting molecules, 
combining improved tumor selectivity with a more 
rapid clearance of unbound conjugates compared to 
mAb-conjugates. 
 
The PS IRDye700Dx shows that it is a potent PDT 
agent because it can result in strong light induced 
cell-killing effects and importantly shows no dark 
toxicity.  
The results show also that the concept of targeted 
PDT, tested in this project, works very well and the 
clear specificity of this PDT approach is underlined. 
Only very high EGFR-expressing cells are targeted 
by the 7D12-IRDye conjugates.  
On the SKOV-3 cells, the cell killing effect is not 
that obvious but there is definitely a decrease in 
relative cell viability (Figure 3). These PDT results 
show a clear correlation with the results from the 
EVOS fluorescent microscopy. Already with the 
EVOS the binding to the EGFR-expressing SKOV-
3 cells cannot be detected anymore. Only after 
treating A431 cells with the 7D12-PS conjugates, a 
clear fluorescent signal could be detected.  
Most likely the amount of binding to the SKOV-3 
cells seems to be too low, resulting in a detection 
problem with the EVOS. In addition, the amount of 
bound PS conjugates does not reach the threshold, 
which is needed for efficient working of PDT as 
well. In contrast, fluorescent microscopy shows a 
very high amount of 7D12-binding on the A431 
cells, making it possible to reach the threshold 
amount of PS molecules which are needed for a 
strong light induced cell killing effect. These 
perceptions correlate very well with the 
characteristics of the cell lines. A431 cells are 




All in all, it was demonstrated that targeting of the 
PS IRDye700Dx with 7D12 lead to specific binding 
of these conjugates to high EGFR-expressing cells 
allowing cell killing of only these cells after 
illumination of the PS.  
 
 
ROLE OF THE STUDENT 
For this research, I have been working as a bachelor 
student and participant of the Honours Programme 
(Radboud University Nijmegen) under the 
supervision of William Leenders. I performed all 
the experiments in collaboration with the rest of his 
team. This paper for the SRC application is a 
shorter version of my bachelor thesis and was fully 
written by myself. 
 
ACKNOWLEDGMENTS 
First, I would like to thank Petri Mäkinen and 
Seppo Ylä-Herttuala (University of Eastern 
Finland, Kuopio, FI) for offering the opportunity to 
perform the PDT experiments at their lab and for 
helping with the experiments. My special thanks go 
to William Leenders and Sander van Duijnhoven, 
my supervisors, and Anneke Navis and Sanne van 
Lith (Radboud UMC Nijmgen, NL) for a great time 




1. Duska, L. R., M. R. Hamblin, et al. (1997). 
"Biodistribution of charged F(ab')2 
photoimmunoconjugates in a xenograft 
model of ovarian cancer." Br J Cancer 
75(6): 837-844. 
2. Oei, A. L., F. C. Sweep, et al. (2008). "The 
use of monoclonal antibodies for the 
treatment of epithelial ovarian cancer 
(review)." Int J Oncol 32(6): 1145-1157. 
3. Sereni, M. I., E. Baldelli, et al. (2014). 
"Functional characterization of epithelial 
ovarian cancer histotypes by drug target-
based protein signaling activation 
mapping: implications for personalized 
cancer therapy." Proteomics. 
4. Heukers, R., P. M. van Bergen En 
Henegouwen, et al. (2014). "Nanobody-
photosensitizer conjugates for targeted 
photodynamic therapy." Nanomedicine 
10(7): 1441-1451. 
5. Dougherty, T. J., C. J. Gomer, et al. 
(1998). "Photodynamic therapy." J Natl 
Cancer Inst 90(12): 889-905. 
6. Kuimova, M. K., M. Bhatti, et al. (2007). 
"Fluorescence characterisation of 
multiply-loaded anti-HER2 single chain 
Fv-photosensitizer conjugates suitable for 
photodynamic therapy." Photochem 
Photobiol Sci 6(9): 933-939. 
7. Staneloudi, C., K. A. Smith, et al. (2007). 
"Development and characterization of 
novel photosensitizer : scFv conjugates for 
use in photodynamic therapy of cancer." 
Immunology 120(4): 512-517. 
8. van Dongen, G. A., G. W. Visser, et al. 
(2004). "Photosensitizer-antibody 
conjugates for detection and therapy of 
cancer." Adv Drug Deliv Rev 56(1): 31-
52. 
